Fleury SA operates within the Medical laboratories sector. In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other pharmaceutical manufacturers in Latin America: Genomma Lab Internacional Sab De Cv of Mexico (2018 sales of 11.79 billion Mexican Pesos [US$613.07 million] of which 103% was PC), Diagnosticos Da America SA (3.93 billion Brazilian Reals [US$940.80 million] of which 100% was servi os auxiliares), and Hypera SA (3.72 billion Brazilian Reals [US$890.78 million] ).

Sales Analysis. During the year ended December of 2018, sales at Fleury SA were 2.66 billion Brazilian Reals (US$637.29 million). This is an increase of 11.8% versus 2017, when the company's sales were 2.38 billion Brazilian Reals. This was the fifth consecutive year of sales increases at Fleury SA (and since 2013, sales have increased a total of 61%). Sales of Diagnostic Medicine saw an increase of 12.0% in 2018, from 1.99 billion Brazilian Reals to 2.23 billion Brazilian Reals.